Intellia Therapeutics
Develops CRISPR gene-editing treatments delivered into the body by lipid nanoparticles, led by nex-z.
NeurologyLive, 28 Jan 2026Prices by TradingView, about 15 minutes delayed. Not investment advice.
- Ticker
- NTLA · Nasdaq
- Based in
- United States
- Website
- intelliatx.com ↗
How nano is it?
No filing of theirs says yet
We flag how much of a business is nanotechnology only when the company's own filings say it. Until then we describe what it makes.
What we track
Its technologies, and how far each has got
On the record
Latest steps
The newest dated events on the technologies above.
- Human trial
In-body gene editing
The FDA lifted the hold on MAGNITUDE-2, the trial in the nerve form of the disease, with closer monitoring of liver tests. The hold on the heart trial, MAGNITUDE, stayed.
NeurologyLive, 28 Jan 2026 - Setback
In-body gene editing
The FDA put Intellia's two phase 3 trials of nex-z on hold after a patient had severe liver injury. The patient died on November 5, 2025.
NeurologyLive, 28 Jan 2026 - Human trial
In-body gene editing
Doctors at Children's Hospital of Philadelphia and Penn Medicine treated a baby, KJ, born with a rare metabolic disease, with a gene-editing therapy made just for him and delivered to his liver in lipid nanoparticles. It was given safely, and he is growing well. The case was published in the New England Journal of Medicine.
Children's Hospital of Philadelphia, 15 May 2025
Not investment advice. We describe what companies do and what their own filings say; we never say whether to buy or sell.